Company Registry

Talee Bio Inc
Profile last edited on: 1/25/2019

Gene therapy company developing next generation treatment and cures for cystic fibrosis
Year Founded
2016
First SBIR Year
2017
Latest SBIR Award
2017
Program Status
Active

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3001 Market Street Suite 140
Philadelphia, PA 19104
   (215) 239-6271
   info@taleebio.com
   www.taleebio.com/
Multiple Locations:   
Congressional District:   03
County:   Philadelphia

Public Profile

Talee Bio is developing a gene therapy for cystic fibrosis (CF), the first curative treatment for this disease. Talee has developed a novel transgene and a number of innovations in a well-characterized delivery vector that collectively will overcome challenges that have previously limited the clinical viability of gene therapy for CF. Rspresenting a collaboration among drug development professionals with more than 60 years of combined experience, and academic founders of the company, from the University of Iowa, who have been investigating CF pathogenesis and treatment, including gene therapy strategies, for more than 25 years.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
15-19
Revenue Range
1.5M-2M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
---
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2017 1 NIH $225,000
A gene therapy for cystic fibrosis using GP64-pseudotyped lentivirus
2017 1 NIH $225,000
A Modified Aav Gene Therapy for Cystic Fibrosis

Key People / Management

  Joan Lau -- CEO and Co-Founder

  Jane Holmes Hollingsworth --

  Eric Yuen -- Chief Medical Officer

SBIR firms in the news

There are no news available.